The exotoxin mycolactone interferes with the biogenesis of the majority of transmembrane proteins and its actions highlight differences in how distinct classes of these proteins initially engage the Sec61 translocon. 
Summary statement:
The exotoxin mycolactone interferes with the biogenesis of the majority of transmembrane proteins and its actions highlight differences in how distinct classes of these proteins initially engage the Sec61 translocon.
Abstract: Mycolactone is the exotoxin virulence factor produced by
Mycobacterium ulcerans, the pathogen responsible for Buruli ulcer. The skin lesions and immunosuppression characteristic of this disease result from the action of mycolactone, which targets the Sec61 complex and inhibits the cotranslational translocation of secretory proteins into the endoplasmic reticulum. In this study, we investigate the effect of mycolactone on the Sec61-dependent biogenesis of different classes of transmembrane protein (TMP). Our data suggest that the effect of mycolactone on TMP biogenesis depends on how the nascent chain initially engages the Sec61 complex. For example, translocation of TMP lumenal domains driven by an N-terminal, cleavable signal sequence is efficiently inhibited by mycolactone. In contrast, the effect of mycolactone on protein translocation driven solely by a non-cleavable signal anchor/transmembrane domain depends on which flanking region is translocated.
For example, while translocation of the region N-terminal to a signal
Introduction
The exotoxin mycolactone is produced by Mycobacterium ulcerans and is the causative agent of Buruli ulcer; a disease characterised by necrotic skin ulcers and immunosuppression (George et al., 1999; Silva et al., 2009; Walsh et al., 2011) .
Mycolactone is linked to the underproduction of several key proteins involved in the inflammatory response (Pahlevan et al., 1999; Simmonds et al., 2009; Torrado et al., 2007) and control of blood coagulation (Ogbechi et al., 2015) as a direct result of its effect on the Sec61 complex at the endoplasmic reticulum (ER; Baron et al., 2016; Hall et al., 2014; Ogbechi et al., 2015; McKenna et al., 2016) .
Secretory proteins contain a cleavable, hydrophobic, N-terminal signal sequence that interacts with the signal recognition particle (SRP) upon emerging from the ribosomal exit tunnel (Blobel and Dobberstein, 1975; Walter et al., 1981) . SRP binding allows the ribosome-nascent chain complex to be delivered to the ER via an interaction with the SRP receptor (Gilmore et al., 1982a; Gilmore et al., 1982b) and is then transferred to the Sec61 complex. Some nascent secretory proteins insert into the Sec61 complex with their N-terminal signal sequence in a looped, or 'hairpin', conformation (Mothes et al., 1994; Voorhees and Hegde, 2016) , which precedes translocation of their mature domain into the ER lumen (Görlich et al., 1992) .
Importantly, these sequences must be sufficiently hydrophobic to destabilise the hydrophobic interactions between transmembrane domains 2 and 7 of the core Sec61 subunit, and thereby open what is known as the 'lateral gate' (Trueman et al., 2012; Voorhees and Hegde, 2016) . Mycolactone does not interfere with SRPdependent delivery of secretory proteins to the ER, but rather prevents their cotranslational translocation, most likely by stabilising the Sec61 complex in a closed conformation (McKenna et al., 2016) by interacting near the lumenal plug of Sec61α (Baron et al., 2016) .
A second major group of proteins that are initially targeted to the ER are the transmembrane proteins (TMPs) that, with the exception of tail-anchored proteins (Kutay et al., 1995) , also depend on both SRP and the Sec61 translocon for entry assumed that the initial stages of their biogenesis are mechanistically similar to the full translocation of secretory proteins (Walter and Lingappa, 1986) , However, whilst it has been demonstrated that the N-terminal signal sequence of type I TMPs initially inserts into the Sec61 translocon as a hairpin (Shaw et al., 1988) , there is surprisingly little additional biochemical evidence to support this hypothesis. An obvious question is therefore: how does mycolactone affect the integration of these distinct classes of TMP?
In this study, we characterise the integration of type I, II and III TMPs and identify clear differences in how these processes are affected by mycolactone. Our findings build upon our current understanding of mycolactone's inhibitory effects on protein translocation at the Sec61 translocon, and highlight the mechanistic diversity in the
Results

TMDs of the type I TMPs CD3δ and GypA can partially rescue their membrane integration in the presence of mycolactone
We previously demonstrated that co-translationally translocated secretory proteins are prevented from accessing the ER lumen due to the inhibitory effect of mycolactone at the Sec61 translocon (Hall et al., 2014; McKenna et al., 2016) . Like secretory proteins, type I TMPs contain a hydrophobic, cleavable signal sequence at their N-terminus ( Table 1 ). In addition, type I TMPs contain a second hydrophobic domain (their TMD) that ultimately spans the ER membrane to generate an integral membrane protein with N-lumenal/C-cytosolic topology (High and Dobberstein, 1992) . Using a reconstituted in vitro system, we tested the T-cell surface glycoprotein CD3 delta chain (CD3δ, Fig. 1A ) for its ability to integrate into ERderived rough microsomes (RMs) in the presence and absence of mycolactone. As a type I TMP, successful insertion of CD3δ is indicated by modification of its two endogenous, N-glycosylation sites contained within the region N-terminal to the TMD (Fig. 1A) . In the presence of mycolactone, we observe a substantial reduction in the amount of glycosylated CD3δ, but note that a small but significant proportion of glycosylated substrate persists (Figs 1B, C and S1A). This behaviour is distinct from the complete block on translocation of secretory proteins that we had tested previously (Hall et al., 2014; McKenna et al., 2016 ; Fig. 1D ). Since only the membrane fractions are analysed from these integration assays, a concomitant increase in non-integrated substrate upon incubation with mycolactone is not necessarily observed. Hence, non-glycosylated species may represent either CD3δ that is peripherally membrane-associated, or that is integrated but not glycosylated.
We concluded that the partial persistence (~25%) of glycosylated CD3δ in the presence of mycolactone could be due to the inherent properties of either its Nterminal signal sequence or its TMD. To test this, we first truncated CD3δ at residue 107 to remove the TMD and thus yield an artificial secretory protein (CD3δ∆TMD).
Glycosylation of CD3δ∆TMD is completely inhibited by mycolactone (Figs 1C and E),
consistent with our previous observations using bona fide secretory proteins (McKenna et al., 2016 ; Fig. 1D ). We therefore addressed the potential role of the CD3δ TMD by introducing a point mutation to increase its net hydrophobicity
Journal of Cell Science • Advance article (CD3δD111L; Fig. 1F ). We speculated that this change might enhance the ability of the TMD to overcome a mycolactone-stabilised closed conformation of Sec61 (Junne et al., 2015; Voorhees and Hegde, 2016 ; see also introduction). Strikingly, we observe almost no loss in CD3δ glycosylation in the presence of mycolactone following this single amino acid substitution (Figs 1C and G) . We made similar observations regarding the mycolactone sensitivity of a second naturally occurring type I TMP, glycophorin A (GypA; Figs S1A-E).
Together, these data demonstrate that type I TMPs are subject to mycolactone-dependent inhibition of the Sec61 translocon but, in contrast to the secretory proteins we studied previously, their subsequent TMD can influence this process.
ER integration of the type I TMP CD3δ in the presence of mycolactone is driven by its TMD
On the basis of their similarity to secretory proteins, it is generally assumed that the signal sequence of a type I TMP is sufficient to both co-translationally target the nascent chain to the Sec61 translocon, and to enable the subsequent translocation of its lumenal domain across the ER membrane. Here, the TMD simply acts as a 'stop-transfer' sequence, halting further translocation of the type I TMP and enabling its release into the ER membrane (Walter and Lingappa, 1986; Fig. 2C(i) ). The data presented in Fig. 1 , however, suggest the TMD does not simply provide a stoptransfer sequence, but indicate that in the presence of mycolactone it can actively promote translocation of the type I TMP lumenal domain. To further investigate the roles of the signal sequence and TMD during its biogenesis, we generated a series of C-terminally truncated versions of the CD3δ mRNA that lack stop codons and so produce ribosome-trapped nascent chains that reflect different stages of its biogenesis (Gilmore et al., 1991) . In the absence of mycolactone, each of these truncations is capable of efficient membrane integration/translocation ( Fig. 2A, top panel, lanes 1, 3, 5, 7, 9, 11), even when the TMD is predicted to be fully/partially obscured by the ribosomal exit tunnel (Cabrita et al., 2016 ; Fig. 2A, bracketed area) or is missing completely (Fig. 2A, lane 11) . These findings support a model where the signal sequence of this type I TMP is normally sufficient for both ER targeting and translocation ( Fig. 2C(i) ). In the presence of mycolactone, however, Nglycosylation is only detectable when CD3δ is 173 residues long (CD3δ173; i.e. fulllength), and even then at a reduced level compared to a vehicle control ( Fig. 2A, top panel, cf. lanes 1 and 2). This suggests that in CD3δ173 the TMD has emerged sufficiently far from the ribosome to enable a productive interaction with the Sec61 translocon, and we speculate that this interaction can partially counteract the inhibitory effect of mycolactone. Similarly, for the equivalent truncations of CD3δD111L, we see maximal rescue of translocation at 173 residues ( Fig. 2A, bottom panel, see arrowhead). Based on the study by Cabrita et al., 2016 we speculate that although the entire TMD of CD3δ158 is beyond the ribosomal exit tunnel ( Fig. 2A, see dashed bracket), it has not emerged sufficiently to form a productive interaction with the Sec61 translocon and therefore remains mycolactone sensitive ( Fig. 2A, lane 4) .
We assume that the low levels of glycosylation of shorter truncations of CD3δD111L in the presence of mycolactone reflect the spontaneous release of some nascent chains from the ribosome (Hentzen et al., 1972) .
In the case of multi-pass TMPs, TMDs of insufficient hydrophobicity can enter the translocon and remain there until a second TMD arrives, at which point the two Fig. 2B(i) and (ii)), demonstrating that they retain the capacity to be targeted to the ER and inserted in the correct (N-lumenal/C-cytosolic) topology.
Furthermore, the extent to which the integration of each construct was inhibited by mycolactone was qualitatively similar to their respective signal sequence-containing versions (cf. Figs 1B and 1G ). We therefore conclude that the extent of mycolactone-sensitivity of CD3δ integration is primarily determined by its TMD.
These findings lead us to propose that some type I TMPs can employ an alternative mechanism for ER translocation in the presence of mycolactone ( Fig. 2C(ii) ), thereby accounting for the portion of substrate that successfully integrates in vitro. In this instance, the signal sequence is sufficient to target the translating ribosome to productively with the Sec61 translocon to retrospectively enable translocation of the lumenal domain. While we assume that the signal sequence and TMD of such type I TMPs engage the same Sec61 translocon during this process (Gogala et al., 2014), we cannot rule out the possibility that the TMD engages a second translocon distinct from the one that has been unsuccessfully engaged by the signal sequence.
The large N-terminal domain of the type I TMP VCAM1 results in a complete block of its membrane integration by mycolactone
The regions separating the signal sequences and TMDs of both CD3δ and GypA are comparatively short (83 and 68 residues, respectively). For this reason, we chose to study the effect of mycolactone on the membrane integration of vascular cell adhesion protein 1 (VCAM1), which possesses an equivalent region of over 600
residues. Notably, we observe no membrane integration of VCAM1 in the presence of mycolactone (Figs 3A and S1A), and hypothesised that its large lumenal domain may explain the lack of a mycolactone-resistant pool. To this end, we generated a shorter version of VCAM1 with only 60 residues separating its signal sequence and TMD ( Fig. 3B, VCAM160 ). Strikingly, we now observe a partial rescue of membrane integration of VCAM160 in the presence of mycolactone, as indicated by signal sequence cleavage and modification of an artificially engineered N-glycosylation site ( Fig. 3C, C52N ). Furthermore, this TMD-dependent effect is enhanced when the hydrophobicity of the VCAM160 TMD is increased by altering a single amino acid residue (Fig. 3D) . In contrast, this more hydrophobic TMD has no effect on the mycolactone-sensitivity of full-length VCAM1 (Fig. S2A) . Upon extending the region between the signal sequence and TMD of VCAM160 by an additional 50 residues (VCAM1110), the partial rescue of protein integration in the presence of mycolactone is lost, even in combination with the more hydrophobic TMD (Figs S2B and C).
These findings highlight the importance of both TMD hydrophobicity and lumenal domain size in conferring mycolactone-sensitivity.
Our characterisation of VCAM1 as a mycolactone-sensitive substrate allows us to draw comparisons with the mechanisms of CAM741, which is a well-defined small molecule that inhibits Sec61-dependent translocation in a highly substrate-specific manner (Besemer et al., 2005) . Previous studies demonstrated that VCAM1
integration is selectively and efficiently blocked by CAM741 on the basis of its signal Furthermore, increasing the net hydrophobicity of the VCAM160 TMD does not reduce the effectiveness of CAM741 inhibition (Fig. 3F) . Therefore, our studies of VCAM1 highlight key differences in the inhibitory mechanisms of the polyketide mycolactone and the cyclopeptolide CAM741 (see Discussion).
Mycolactone does not interfere with type III TMP integration
We next sought to study the effect of mycolactone on a naturally occurring membrane protein that has the same final topology as a type I TMP, but that lacks an N-terminal signal sequence. Glycophorin C (GypC) is a naturally occurring type III single-pass transmembrane protein (type III TMP; High and Tanner, 1987) , and so depends on an internal TMD to both target the nascent polypeptide to the ER and anchor it in an N-lumenal/C-cytosolic topology within the ER membrane (see Table   1 ). Strikingly, the integration of GypC into RMs is unaffected by mycolactone ( To establish if mycolactone affects GypC at a stage before its complete membrane integration, we again used truncated mRNAs to generate ribosome-trapped nascent chains (Fig. 4E) . Furthermore, in order to specifically focus on the translocation status of nascent, ribosome-associated GypC polypeptides, we analysed the glycosylation status of GypC peptidyl-tRNA species (Borel and Simon, 1996; Fig.   4F ). Glycosylation, and hence N-terminal translocation, was observed for GypC110 peptRNA, where the TMD is predicted to be partially obscured by the ribosomal exit tunnel (Cabrita et al., 2016) , as well as GypC122 peptRNA, where the TMD is likely fully exposed (Figs 4E and F) . In the presence of mycolactone, however, glycosylation of GypC110 peptRNA is lost, while that of GypC122 peptRNA is maintained (Fig. 4F) . GypC is therefore sensitive to mycolactone at some point during its biogenesis, but achieves mycolactone-resistance when the TMD is sufficiently beyond the ribosomal exit tunnel.
To investigate the effect of mycolactone on the interacting partners of these GypC integration intermediates, we introduced a single cysteine at either the N-terminal (*(52)) or C-terminal (*(84)) side of its TMD (Fig. 4E) . This allowed us to generate cysteine-cysteine cross-links upon addition of bis-maleimidohexane (BMH). In the absence of mycolactone, we observe C52-Sec61α adducts with the shortest GypC truncations (GypC110 and GypC115; Fig. S3B and Fig. 4G , top left panel, see arrowheads). These adducts are N-glycosylated ( Fig. S3C) and therefore represent N-terminally translocated nascent GypC polypeptides. Furthermore, these adducts are lost upon disruption of the ribosome-nascent chain complex following treatment with puromycin ( Fig. S3D) , thus demonstrating that they reflect the environment of bona fide trapped integration intermediates. Extension of the nascent chain by just seven residues (to GypC122) results in a concomitant loss of C52 adducts and an increase in both C84-Sec61α and C84-Sec61β adducts ( Fig. S3B and Fig. 4G , top two panels). When the same analysis is performed in the presence of mycolactone, the Sec61α adducts with GypC110 and GypC115 are lost, while those of the two longer intermediates are maintained (Figs 4G, bottom panels, and S3D), consistent with the acquisition of mycolactone-resistance at these longer chain lengths (Fig. 4F) .
Together, these data show that type III TMP integration at the ER is highly resistant to mycolactone, even when these substrates possess TMDs of relatively modest hydrophobicity. Additionally, our data suggest that only a portion of the GypC TMD needs to be exposed in order for N-terminal translocation to occur, but that these truncated polypeptides are transiently mycolactone-sensitive. Acquisition of mycolactone-resistance occurs when the C-terminus of GypC is extended by just a few residues, at which point the TMD is most likely fully exposed from the ribosome.
Mycolactone efficiently blocks type II TMP integration
While N-terminal signal sequence-driven translocation of polypeptides through the Sec61 translocon is efficiently blocked by mycolactone, its effects on the TMD-driven translocation of the substrates we have so far investigated appears more variable.
One possible explanation for this observation is that TMDs tend to be longer and Journal of Cell Science • Advance article more hydrophobic than N-terminal signal sequences (Heijne, 1985; Heijne, 1986) , and this may enable them to overcome the effects of mycolactone more successfully. Alternatively, the differences we observe may be determined by whether the region that is being translocated is N-or C-terminal to the hydrophobic ER targeting sequence that engages the Sec61 complex. For example, while an Nterminal signal sequence translocates the region to its C-terminus, the TMDs of type III TMPs (Kida et al., 2000) , and type I TMPs when analysed in the presence of mycolactone (this study), translocate regions that are to their N-terminus.
We therefore studied the MHC class II-associated invariant chain (Ii, Fig. 5A Ii with a truncated C-terminus (IC125, Fig. 5F ), thus ruling out the possibility that its sensitivity is due to the larger size of its lumenal domain.
Despite the strong inhibitory effect of mycolactone on Ii integration, we observe surprisingly little change in the cross-linking profile of ribosome-trapped nascent chains of various lengths when mycolactone is present (Figs 5G and 5H) . What we do find is that the full membrane integration of Ii following puromycin-mediated release from the ribosome is prevented by mycolactone. Instead, the nascent chain is retained in proximity to the translocon, as indicated by continued cross-linking to Sec61α in the presence of mycolactone (Fig. 5I) . We therefore conclude that mycolactone prevents the type II TMP Ii from assuming its correct N-cytosolic/Clumenal topology, and instead causes the nascent chain to be retained at a preintegration step (see Discussion).
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Mycolactone sensitivity is dependent upon which TMD-flanking region is translocated
The observations in this study with type II and type III TMPs suggest that mycolactone sensitivity may be dependent on whether the region that is translocated through the Sec61 complex lies N-or C-terminal to the TMD. These comparisons have so far relied on substrates that vary in several factors known to contribute to final protein topology, including TMD hydrophobicity, relative position of the TMD, and the number and location of charged residues flanking the TMD. To address these issues, we generated a chimeric protein that contains Ii downstream of a preprolactin signal sequence (PPL-Ii, Fig. 6A(i) ) with the intention of promoting the unnatural N-terminal translocation of this artificial protein across the ER membrane.
We therefore expected to observe either cleavage of the N-terminal signal sequence ( Fig. 6A(ii) ) or N-glycosylation of the C-terminal region ( Fig. 6A(iii) . 1D ), and we observe no contribution of the signal sequence to the mycolactone-resistance of TMD-containing proteins (Fig. 2B) , both final topologies of PPL-Ii in the presence of mycolactone must result from membrane integration enabled by the TMD. We therefore conclude that even when membrane integration in two different topologies can be driven by the same TMD, translocation of its C-terminal region is preferentially inhibited by mycolactone.
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Mycolactone traps headfirst-inserting type II TMPs in an N-lumenal/C-cytosolic topology
Previous studies suggest that type II TMPs can engage the Sec61 translocon in one of two ways, depending largely on the size of their N-terminal domain. Those with an N-terminal domain longer than ~20 residues, like our model type II TMP, Ii, are generally believed to insert as a hairpin, while those with an N-terminal domain shorter than ~20 residues are proposed to insert headfirst, like a type III TMP, before fully inverting within the translocon (Devaraneni et al., 2011; Kocik et al., 2012; Table   1 ). To look more closely at the effect of mycolactone on these two alternative modes of type II TMP insertion, we used the asialoglycoprotein receptor subunit H1 ( Fig. 7E(i) ). These results therefore suggest that type II TMPs that employ a headfirst-inversion mode of insertion into the ER may be prevented from inverting within the Sec61 translocon by mycolactone, and instead become integrated into the ER membrane in an N-lumenal/C-cytosolic topology ( Fig. 7E(ii) and (iii) ).
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Discussion
In this study, we explore the inhibitory mechanism of mycolactone at the Sec61 translocon by investigating the integration of three distinct classes of single-pass transmembrane proteins (TMPs). We conclude that mycolactone binding restricts the Sec61 complex leading to disruption of TMP biogenesis. However, distinct classes of TMP respond differently to mycolactone, most likely reflecting the precise nature of their initial engagement at the translocon Thus, whilst the headfirst insertion of polypeptides is unaffected, their hairpin insertion into, and inversion within, the translocon are inhibited.
What makes a protein mycolactone-sensitive?
Secretory and membrane proteins are key therapeutic targets, and it is important to understand the molecular basis for the selectivity of inhibitors that affect their biogenesis (Kalies and Römisch, 2015) . For the majority of small molecules known to modulate ER translocation, they appear to do so by acting directly at the Sec61 complex (Kalies and Römisch, 2015) . Compounds such as eeyarestatin and apratoxin inhibit the Sec61-dependent translocation of a broad range of substrates (Cross et al., 2009a; Paatero et al., 2016) . In contrast, and despite their common Sec61 target, HUN-7293-derived compounds such as CAM741 and the cotransin family display clear substrate specificity (Besemer et al., 2005; Garrison et al., 2005; Maifeld et al., 2011) . Exactly why certain compounds have different substrate specific effects on ER translocation is unclear, and it is in this context that we are studying the effects of mycolactone, which we previously showed to have a broad ranging effect on the co-translational translocation of secretory proteins across the ER membrane (Hall et al., 2014; McKenna et al., 2016) . et al., 1994; Shaw et al., 1988; Voorhees and Hegde, 2016) . Taken together, our findings therefore suggest that polypeptides that initially engage the Sec61 translocon as a hairpin are effectively prevented from correctly integrating/translocating into the ER. In contrast, headfirst insertion of polypeptides into the Sec61 translocon can still occur,, but those substrates that require a subsequent inversion step within the translocon are prevented from doing so.
Our conclusion that the type II TMP Ii is trapped at a 'pre-integration' stage by mycolactone is supported by a previous study of membrane protein biogenesis using the cotransin, CT8 (MacKinnon et al., 2014) . Ii closely resembles TNFα, the model substrate used in this previous study (Fig. 5G) . In both cases, similarly positioned
Journal of Cell Science • Advance article cysteine residues form adducts with components of the Sec61 translocon that are lost following full integration into the ER membrane, but that are maintained in the presence of mycolactone/CT8. Moreover, mutagenesis of Sec61α and competitive binding assays show that CT8 and mycolactone most likely have overlapping binding sites (cf. Baron et al., 2016 and MacKinnon et al., 2014) . Whilst these similarities suggest the inhibitory mechanisms of these two small molecules are related, there is notably little effect of CT8 on the biogenesis of other mycolactone-sensitive substrates, such as pre-prolactin (Maifeld et al., 2011; McKenna et al., 2016) , highlighting clear differences between them. Furthermore, our investigation of the type I TMP VCAM1 distinguishes the mechanism of inhibition of mycolactone from that of the cotransin-like compound, CAM741. While CAM741 blocks integration in a signal sequence-specific manner that prevents productive interactions of a subsequent TMD with the Sec61 translocon, mycolactone indiscriminately interferes with signal sequence-mediated protein translocation, but its effect can be partially overcome by sufficiently hydrophobic TMDs.
To date, the focus for identifying mycolactone-sensitive substrates in a cellular context has been on mediators of the immune response and blood anticoagulation.
Both secreted mediators, such as cytokines and chemokines, as well as TMPs, such as receptors, are under-produced in cells treated with mycolactone, while cytoplasmic substrates appear to be consistently unaffected (Coutanceau et al., 2007; Hall and Simmonds, 2014; Simmonds et al., 2009) . Our current study suggests that type I TMPs with N-terminal domains of more than ~100 residues are highly sensitive to mycolactone treatment in vitro. Notably, most of the type I TMPs that are mycolactone-sensitive at a cellular level have N-terminal domains of a similar or larger size (cf. Hall and Simmonds, 2014), including thrombomodulin, consistent with the previously suggested mycolactone-dependent inhibition of its ER translocation (Ogbechi et al., 2015) . Our limited in vitro analysis of type II TMPs suggests that their membrane integration is highly sensitive to mycolactone, and is consistent with previous observations using TNFα (Hall et al., 2014) . In contrast to our observations with type I and type II TMPs, we find that type III TMP integration appears to be completely resistant to mycolactone. Strikingly the only type III TMP to be studied at a cellular level, linker for activation of T-cells family member 1 (LAT), was also unaffected by mycolactone treatment (Boulkroun et al., 2010) . Estimates
Journal of Cell Science • Advance article
suggest that human type III TMPs represent only ~2% of all single-spanning membrane proteins (Uniprot), and hence the majority of single-spanning TMPs are likely to display some degree of mycolactone-sensitivity. In line with this, a recent study reported that the majority of Sec61-dependent substrates that could be identified were sensitive to mycolactone, with single-pass TMPs being particularly enriched (Baron et al., 2016) . In short, our findings provide a potential molecular basis for the complex changes in membrane protein expression that underlie the pathogenesis of Buruli ulcer.
What can mycolactone tell us about Sec61-dependent translocation?
The substrate-specific inhibition of Sec61-dependent translocation by mycolactone that we describe in this study supports the idea that the TMD of a nascent polypeptide plays an important role in opening the Sec61 lateral gate. A recent study using native membranes concluded that full opening of the Sec61 translocon appears to occur upon the docking of even non-translating ribosomes (Pfeffer et al., 2015) . In contrast, our findings align more closely with a model where ribosome docking primes the Sec61 translocon by partially opening its lateral gate. In this model, full opening occurs only when a sufficiently hydrophobic signal sequence/TMD of the nascent polypeptide chain positionally replaces one of the Sec61α TMDs located at the lateral gate, thereby exposing the hydrophobic region to the lipid phase of the ER membrane (Voorhees and Hegde, 2016 ). An interesting implication of our study is that opening of the lateral gate may occur more readily when a substrate engages the translocon in a particular orientation (namely headfirst), regardless of its hydrophobicity. Recent structural studies of the engaged Sec61 translocon have greatly advanced our knowledge of ER translocation (Gogala et al., 2014; Voorhees and Hegde, 2016) , but have so far only investigated a narrow range of Sec61-dependent substrates. Our findings demonstrate the substratedriven complexity of Sec61-dependent protein translocation and therefore highlight the importance of considering a broad range of substrates in future structural studies aiming to characterise this process.
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Materials and methods
Synthetic mycolactone A/B was a gift from Yoshito Kishi, Harvard University (Song et al., 2002) . CAM741 was generously provided by Boehringer. Unless otherwise stated, all standard laboratory reagents were obtained from Merck or Sigma.
DNA constructs
Unless otherwise stated, all cDNAs were from H. sapiens. GypC, GypA and Ii (M.
musculus; Oliver et al., 1995) , PPL (B. Taurus; McKenna et al., 2016) Liverpool, UK). The PPL-Ii chimera was generated by cloning Ii downstream of PPL using an engineered EcoRI site. Point mutations were generated using primers from Eurogentec. cDNAs were generated by PCR and transcribed with T7 polymerase (Promega).
Antibodies
Rabbit antiserum against GypC was as described previously (Elliott et al., 1997) .
Rabbit antiserum against Sec61α was from Richard Zimmermann (University of Saarland, Homburg, Germany). Rabbit antisera against Sec61β and Ii were from Bernhard Dobberstein (University of Heidelberg, Heidelberg, Germany).
In vitro translation/translocation assays
In vitro translations were as described previously (McKenna et al., 2016) , except that reaction volumes were 20 µl and were incubated at 30°C for 15 minutes. For crosslinking assays, translation reactions were carried out at 30°C for 10 minutes. All samples were then treated with 0.5 mM puromycin and incubated at 30°C for 5 minutes unless stated otherwise in the figure legends. For CAM741 inhibition assays, CAM741 (in DMSO) was added to the appropriate concentration at the beginning of the reaction. Control was an equivalent volume of DMSO.
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Membrane recovery and visualisation
Membranes were recovered as described previously (McKenna et al., 2016) . Unless stated otherwise in the figure legends, the membrane pellet was immediately resuspended in 30 µl SDS sample buffer [100 mM Tris-HCl, pH6.8, 100 mM DTT,
Bromophenol blue]. Where indicated, samples were also treated with EndoglycosidaseH (EndoH; New England Biolabs) as described by the supplier. The resulting samples were analysed and processed as described previously (McKenna et al., 2016) . Data were quantified using Aida (Raytek) and statistical analyses (Oneway ANOVA or Two-way ANOVA) were performed using GraphPad (Prism). The exact sample size (n) for each experimental group is provided in the appropriate figure legends. In each case, n was defined by the number of times the substrate was tested in the same experimental system.
Cross-linking and carbonate extraction
After recovery the entire pellet was resuspended in 20 µl low salt buffer [100 mM sucrose, 100 mM KOAc, 5 mM Mg(OAc)2, 50 mM Hepes-KOH pH 7.9, 1 mM DTT].
Cross-linking (using BMH (1 mM final)) and carbonate extraction were performed as described previously (McKenna et al., 2016) . Samples were then either analysed directly by SDS-PAGE, or were first immunoprecipitated under denaturing conditions (see below).
Denaturing immunoprecipitation
Following carbonate extraction and recovery of the membrane fraction, pellets were resuspended in 20 µl of 1% (w/v) SDS and incubated for 10 minutes at 70°C. 10 volumes of Triton IP buffer [10 mM Tris-HCl pH 7.5, 140 mM NaCl, 1 mM EDTA, 1%
Triton X-100, 5 mM PMSF, 1 mM methionine] with the appropriate antiserum (1:200)
were added. Samples were incubated for 15 hours at 4°C with constant agitation.
Protein A-sepharose beads (Genscript) were added to 10% (v/v) and samples were incubated at 4°C for a further 2 hours. Protein A-sepharose beads were then recovered by spinning at 13,000 g for 1 min and washed with Triton IP buffer before being heated at 70°C for 10 minutes in SDS sample buffer.
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Native immunoprecipitation of PPL-Ii
Instead of recovering RMs by ultracentrifugation, PPL-Ii translations (see Cell Sci. 130: doi:10.1242/jcs.198655: Supplementary information 
